The Middleman Mentality Is Killing American Medicine

American medicine is brilliant at miracles and strangely bad at receipts. A surgeon can replace a knee, a pharmacist can explain a medication with the patience of a kindergarten teacher on picture day, and a primary care doctor can spot trouble in a ten-minute visit. Then the bill arrives, and suddenly everyone needs a treasure map, a translator, and perhaps a small legal team.

The problem is not that every middleman in healthcare is useless. Insurance plans, pharmacy benefit managers, claims processors, care coordinators, billing systems, and administrators can serve real functions. The problem is the middleman mentality: the idea that healthcare becomes “better” by adding another approval gate, another pricing layer, another opaque contract, another portal password, another entity that collects a fee before care reaches the patient.

In theory, these players are supposed to organize chaos. In practice, too many have learned to profit from chaos. The result is a healthcare system where patients are treated as paperwork, doctors become unpaid data-entry clerks, pharmacies fight invisible pricing rules, and employers pay more every year while getting a benefits package that requires a decoder ring.

What Is the Middleman Mentality in Healthcare?

The middleman mentality is a business approach that thrives between the person who needs care and the person who provides it. It does not always create better medicine. It creates checkpoints. It creates leverage. It creates delay. Most importantly, it creates opportunities to collect money from transactions that patients do not understand and often cannot avoid.

In American medicine, middlemen include health insurers, pharmacy benefit managers, third-party administrators, claims clearinghouses, utilization review companies, group purchasing organizations, revenue-cycle vendors, referral networks, and data platforms. Some are necessary. Many do useful work. But when the system rewards complexity more than clarity, the middleman stops being a helper and becomes a tollbooth.

Think of it this way: if healthcare were a restaurant, the doctor would cook the meal, the patient would eat it, and the bill would be clear. American healthcare adds a menu consultant, a napkin utilization manager, a sauce preauthorization vendor, a rebate negotiator, and a company that denies your fork because you did not prove “medical necessity.” Delicious? Not exactly.

The Numbers Tell a Painful Story

The United States spends more on healthcare than any other high-income country, yet Americans do not consistently get better outcomes for that money. National health expenditures reached about $5.3 trillion in 2024, or more than $15,000 per person. Healthcare consumed roughly 18 percent of the country’s gross domestic product. That is not a healthcare sector; that is an economic weather system.

For families, the pressure is immediate. Employer-sponsored insurance premiums have continued climbing, with family coverage approaching the cost of a small car every year. Deductibles have also risen over time, meaning many insured Americans still hesitate before seeing a doctor because “insured” does not always mean “affordable.” It often means “you may now begin your financial obstacle course.”

Administrative spending is a major part of the story. Billing, coding, eligibility checks, claim edits, prior authorization, payment appeals, network management, and contract disputes consume money and human energy before anyone’s blood pressure is checked. Every form has a cost. Every denial has a cost. Every hour a nurse spends arguing with a portal is an hour not spent helping a patient.

Pharmacy Benefit Managers: The Middlemen Everyone Is Finally Watching

Pharmacy benefit managers, or PBMs, were originally created to help health plans manage prescription drug benefits. They negotiate with drug manufacturers, build formularies, process pharmacy claims, and set reimbursement terms. In a clean system, PBMs would help lower drug costs. In the real system, their incentives can become murky enough to make a swamp look transparent.

The largest PBMs control a huge share of prescription drug claims. They sit between drug manufacturers, insurers, employers, pharmacies, and patients. They negotiate rebates and discounts, but patients do not always see those savings at the pharmacy counter. In some arrangements, higher list prices can produce larger rebates, which may help a plan sponsor on paper while leaving a patient with an ugly copay at the counter.

This is why insulin, cancer drugs, heart medications, and specialty generics have become central examples in the debate. Patients hear that “discounts were negotiated,” yet their wallet experiences the opposite. Independent pharmacies also complain that reimbursement formulas can make it difficult to stay open, especially in rural communities where the local pharmacy may be the closest healthcare access point for miles.

The PBM debate is not simple. Drug manufacturers set list prices. Insurers design benefits. Employers choose plans. Pharmacies operate under contracts. But PBMs are powerful because they influence which drugs are covered, how much pharmacies are paid, how rebates flow, and which patients face barriers. When one middleman controls the maze, it is fair to ask whether the maze is there for savings or for strategy.

Prior Authorization: The Art of Delaying the Obvious

Prior authorization is another famous child of the middleman mentality. The concept sounds reasonable: before paying for expensive tests, procedures, or medications, insurers want confirmation that the care is appropriate. Nobody wants wasteful medicine. Nobody wants unnecessary scans. Nobody wants a system where every sore elbow gets a luxury MRI and a commemorative tote bag.

But prior authorization has expanded far beyond common-sense review. Doctors and patients now face approval requirements for imaging, medications, surgeries, rehabilitation, home care, and sometimes routine treatments. The process can delay care, increase anxiety, and bury medical offices in forms. A physician may know what a patient needs, but the treatment can still sit behind a digital gate guarded by a fax machine from 1998.

The harm is not merely inconvenience. A delayed medication can mean worsening symptoms. A delayed scan can mean a later diagnosis. A delayed discharge plan can mean a longer hospital stay. For patients with chronic illness, prior authorization can turn every refill into a suspense thriller: “Will I get my medication this month, or will I spend Tuesday on hold listening to flute music?”

Federal regulators have pushed for electronic prior authorization, shorter decision timelines, better data sharing, and more transparency. Those reforms matter. But the deeper question remains: why is so much clinical judgment being second-guessed by entities that often do not see the patient, examine the patient, or live with the consequences of delay?

How Middlemen Turn Price Into a Magic Trick

American healthcare prices are famously difficult to understand. A hospital may have a list price, a negotiated insurer price, a cash price, a patient responsibility estimate, and a final bill that arrives weeks later wearing a fake mustache. Price transparency rules have forced hospitals and insurers to publish more data, but data alone does not equal clarity.

Middlemen thrive when prices are hidden, fragmented, or negotiable only by insiders. The patient rarely knows the true cost before care. The doctor often does not know what a patient’s plan will pay. The employer may not fully understand the contract. The insurer may blame the provider. The provider may blame the insurer. Everyone points across the room while the patient stands in the middle holding a bill the size of a beach towel.

This opacity is not an accident. Complex pricing creates leverage. It allows different parties to claim savings, discounts, network value, and “allowed amounts” without giving patients a simple answer to the question: “What will this cost me?” In most industries, a customer can compare prices before buying. In healthcare, people often compare prices after the service, during a mild panic attack.

The Human Cost: Doctors Burn Out, Patients Give Up

The middleman mentality does not only inflate dollars. It drains trust. Patients begin to suspect that every denial is a tactic. Doctors begin to feel that the system doubts their judgment by default. Nurses, pharmacists, and office staff spend hours solving administrative puzzles that would make a tax accountant blink twice.

Burnout is not just about long hours. It is about moral injury: knowing what a patient needs, then watching a nonclinical process delay or block it. A doctor who spends the evening appealing a denial is not doing “paperwork.” That doctor is fighting a system that has placed bureaucracy between knowledge and action.

Patients experience their own version of burnout. They postpone care because the bill is unpredictable. They skip medications because the copay jumps. They abandon appointments because the referral process feels impossible. They lose faith because healthcare begins to feel less like a healing profession and more like a subscription service with surprise penalties.

Specific Examples of the Middleman Problem

1. The Patient Who Has Insurance but Cannot Use It

A patient pays premiums every month, chooses an in-network doctor, and finally schedules a needed scan. Then the insurer requires prior authorization. The doctor submits records. The request is denied. The office appeals. The patient waits. The scan eventually gets approved, but weeks have passed. The insurer may say the process prevents waste. The patient experiences it as paid coverage hiding behind a locked door.

2. The Pharmacist Caught Between Contracts

An independent pharmacist wants to fill prescriptions and counsel patients. Instead, the pharmacy must navigate reimbursement rules, clawbacks, preferred networks, and audit risks. Sometimes the payment for a drug may not cover acquisition cost. The patient asks why the price is so high. The pharmacist may not be allowed to fully explain the contract terms. Everyone is frustrated except the spreadsheet.

3. The Employer Buying Benefits in the Fog

Employers sponsor coverage for millions of Americans, but many struggle to see exactly where the money goes. A benefits package can include insurer fees, PBM arrangements, network access charges, consulting costs, stop-loss coverage, and rebate flows. Even a well-meaning employer may be buying healthcare through a foggy windshield. When costs rise, workers often absorb the pain through higher premiums, deductibles, or narrower choices.

Why “More Management” Does Not Always Mean Better Care

Healthcare absolutely needs management. Complex systems require coordination, fraud prevention, safety checks, and quality measurement. The question is not whether healthcare should be managed. The question is whether management has become detached from care.

When management improves outcomes, it is valuable. When it reduces duplicate testing, catches dangerous drug interactions, or helps a patient transition safely from hospital to home, it earns its place. But when management simply creates friction, extracts fees, or shifts costs in ways patients cannot see, it becomes a parasite wearing a lanyard.

The best healthcare systems simplify the path from need to treatment. The American system often adds lanes, tolls, gates, exits, and warning signs. Then it congratulates itself for building a bigger road.

What Reform Should Look Like

Fixing the middleman problem does not mean abolishing every intermediary. It means forcing every intermediary to prove value. If a company stands between patient and care, it should have to answer three questions: Does it reduce total cost? Does it improve outcomes? Does it make care easier to access?

First, drug pricing needs real transparency. Rebates, spread pricing, pharmacy reimbursement, and formulary incentives should be visible to plan sponsors and regulators. Savings should reach patients at the point of sale, especially for drugs people need to survive.

Second, prior authorization should be limited, fast, electronic, and accountable. Plans should publish denial rates, approval times, appeal outcomes, and the clinical basis for decisions. Repeatedly approved therapies for stable chronic conditions should not require endless reapproval. A patient with diabetes should not have to annually prove that diabetes did not wander off over the summer.

Third, price transparency must become usable. Posting giant machine-readable files is a start, but patients need clear estimates before care. Employers need access to claims and contract data. Doctors need cost information inside clinical workflows. Transparency should not require a data science degree and a heroic tolerance for spreadsheets.

Fourth, administrative simplification should be treated as patient safety. Every unnecessary form is a small delay. Every delay can become harm. Standardized electronic transactions, cleaner eligibility checks, automatic renewal for chronic therapies, and simplified appeals could save billions while giving clinicians time back.

Finally, healthcare policy should reward direct value instead of strategic complexity. The system should pay for better care, fair prices, faster access, and improved outcomes. It should not reward entities merely because they are positioned between money and medicine.

Conclusion: Medicine Needs Fewer Tollbooths

The middleman mentality is killing American medicine because it changes the mission. Healthcare should begin with the patient and organize around healing. Too often, it begins with contracts and organizes around control.

American medicine does not lack talent. It has world-class clinicians, researchers, hospitals, pharmacies, and innovators. What it lacks is simplicity. The country has built a system where too many players can make money from confusion, delay, and opacity. That is not sustainable. It is not ethical. It is also deeply annoying, which is not a technical policy term but should be.

The future of American healthcare depends on a basic reset: fewer tollbooths, clearer prices, faster approvals, honest drug costs, and middlemen who earn their keep. If an intermediary truly adds value, keep it. If it only adds friction, shrink it. If it profits from patients not understanding the system, expose it.

Medicine should not feel like a negotiation with a locked vending machine. It should feel like care. Until America remembers that, the middleman mentality will keep draining money, trust, and time from the people the system exists to serve.